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Abstract
The	ghrelin	receptor	(nomenclature	as	agreed	by	the	NC-IUPHAR	Subcommittee	for	the
Ghrelin	receptor	[19])	is	activated	by	a	28	amino-acid	peptide	originally	isolated	from	rat	stomach,
where	it	is	cleaved	from	a	117	amino-acid	precursor	(GHRL,	Q9UBU3).	The	human	gene	encoding
the	precursor	peptide	has	83%	sequence	homology	to	rat	prepro-ghrelin,	although	the	mature
peptides	from	rat	and	human	differ	by	only	two	amino	acids	[74].	Alternative	splicing	results	in	the
formation	of	a	second	peptide,	[des-Gln14]ghrelin	with	equipotent	biological	activity	[49].	A	unique
post-translational	modification	(octanoylation	of	Ser3,	catalysed	by	ghrelin	Ο-acyltransferase
(MBOAT4,	Q96T53)	[133]	occurs	in	both	peptides,	essential	for	full	activity	in	binding	to	ghrelin
receptors	in	the	hypothalamus	and	pituitary,	and	for	the	release	of	growth	hormone	from	the
pituitary	[58].	Structure	activity	studies	showed	the	first	five	N-terminal	amino	acids	to	be	the
minimum	required	for	binding	[4],	and	receptor	mutagenesis	has	indicated	overlap	of	the	ghrelin
binding	site	with	those	for	small	molecule	agonists	and	allosteric	modulators	of	ghrelin	function	[44].
An	endogenous	antagonist	and	inverse	agonist	called	Liver	enriched	antimicrobial	peptide	2	(Leap2),
expressed	primarily	in	hepatocytes	and	in	enterocytes	of	the	proximal	intestine	[35,	68]	inhibits
ghrelin	receptor-induced	GH	secretion	and	food	intake	[35].	The	secretion	of	Leap2	and	ghrelin	is
inversely	regulated	under	various	metabolic	conditions	[71].	In	cell	systems,	the	ghrelin	receptor	is
constitutively	active	[45],	but	this	is	abolished	by	a	naturally	occurring	mutation	(A204E)	that	results
in	decreased	cell	surface	receptor	expression	and	is	associated	with	familial	short	stature	[93].
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